TAZEMETOSTAT

Search structure
Synonyms:
Status: Approved (2020)
Entry Type: Small molecule
Molecule Category: UNKNOWN
UNII: Q40W93WPE1

Structure
InChI Key NSQSAUGJQHDYNO-UHFFFAOYSA-N
Smile CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
InChI
InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)

Physicochemical Descriptors

Property Name Value
Molecular Formula C34H44N4O4
Molecular Weight 572.75
AlogP 4.73
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 9.0
Polar Surface Area 86.9
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 42.0

Pharmacology

Primary Target
enhancer of zeste 2 polycomb repressive complex 2 subunit
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Transferase
- 4 - - 9.797-13.41
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb
- - - - -2.13-9.93
Epigenetic regulator Writer Protein methyltransferase
5-200 0.34-200 0.09348-11.55 2.5-2.5 -
Other nuclear protein
- 4 - - -
Transcription factor
- 4 - - -
Unclassified protein
- 2-40 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Sarcoma 3 D012509 ClinicalTrials
Lymphoma, Follicular 3 D008224 ClinicalTrials
Lymphoma, Follicular 3 D008224 ClinicalTrials
Mesothelioma 2 D008654 ClinicalTrials
Urinary Bladder Neoplasms 1 D001749 ClinicalTrials
Urinary Bladder Neoplasms 1 D001749 ClinicalTrials
Carcinoma, Squamous Cell 1 D002294 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 1 D016403 ClinicalTrials
Lymphoma 1 D008223 ClinicalTrials
Prostatic Neoplasms 1 D011471 ClinicalTrials

Related Entries

Scaffolds

Cross References

Resources Reference
CAS NUMBER 1403254-99-8
ChEMBL CHEMBL3414621
DrugBank DB12887
DrugCentral 5380
FDA SRS Q40W93WPE1
Guide to Pharmacology 7011
PubChem 66558664
SureChEMBL SCHEMBL13276848
ZINC ZINC000100285161
CONTENTS